# Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL

> **NCT05594784** · PHASE2 · COMPLETED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 79 (actual)

## Conditions studied

- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Olverembatinib
- **DRUG:** Venetoclax
- **DRUG:** prednisone
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT05594784
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-08
- **Primary completion:** 2025-03-25
- **Final completion:** 2025-03-25
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05594784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05594784, "Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05594784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*